Bionor Pharma ASA : Bionor Pharma Appoints Synne H Røine as Chief Financial
The Appointment Strengthens Bionor Pharma's Management Team and Presence in
the Financial Market
(Oslo, Norway 1 March 2013) Bionor Pharma ASA (OSE: BIONOR) today announced
that Synne H Røine has been appointed Chief Financial Officer of Bionor Pharma
ASA, and will start 1 June 2013 at the latest.
Synne H Røine (33) has held the position as Chief Financial Officer of Pronova
BioPharma ASA since July 2009. She is a Norwegian citizen.
"Synne Røine is a highly competent CFO with relevant experience from a fast
growing public biotech company," says CEO Dr. Anker Lundemose. "I strongly
feel she will be able to add significant value to Bionor Pharma. I am pleased
to welcome her onboard the team and look forward to working with her in the
exciting times ahead of us".
Ms Røine holds a Master's degree in business administration from Université
des Sciences Sociales, Toulouse, France. She has worked in Pronova since 2005
where she has played a key role in Pronova's financial team from the IPO in
2007 to the acquisition of the company by BASF in January 2013. Ms. Røine has
held various positions in Pronova through which she has gained broad
operational, financial and strategic experience.
Bionor Pharma ASA
Dr. Anker Lundemose, CEO
Hilde Aalling Syvertsen,
-Director Communications & Corporate Affairs
Tel +47 23 01 09 60
About Bionor Pharma ASA
Bionor Pharma is a leading vaccine company, listed on the Oslo Stock Exchange.
The Company's investments in developing therapeutic vaccines exceed US$ 80
million, and the Company has secured funding of planned scientific and
business related activities until mid 2014.
Bionor Pharma's vaccines are based on the proprietary technology platform
developed following more than two decades of research on peptides, and they
are designed to safely stimulate the immune system to combat viral diseases.
HIV vaccines - foremost in the development
The Company's lead HIV candidate, Vacc-4x, has been investigated as a
therapeutic vaccine in a large exploratory phase II randomized, multinational
(USA and 4 European countries), double-blind, placebo-controlled study. This
study showed a statistically significant reduction in viral load. Bionor
Pharma`s second HIV vaccine candidate, Vacc-C5, is designed to induce
antibodies that potentially can reduce the harmful hyperactivation of the
immune system caused by HIV infection, which leads to AIDS.
Bionor Pharma is currently conducting three clinical studies:
1. Vacc-4x in combination with Celgene`s immune modulator Revlimid®
(Lenalidomide), in patients who fail to regain a normal immune system despite
having a well-controlled viral load on conventional HIV medication
(antiretroviral therapy, ART). The researchers at four clinics in Germany will
in this placebo-controlled study investigate whether Revlimid enhances the
effect of Vacc-4x.
2. Reboosting with Vacc-4x in patients from the phase II study (USA and 4
European countries), to investigate whether this can result in a further
reduction in viral load. Approximately 30-40 patients from the large phase II
study with Vacc-4x will take part at 10 clinics.
3. Clinical phase I/II study with Vacc-C5, at Oslo University Hospital will
investigate safety and efficacy, and whether this vaccine leads to increased
formation of antibodies against HIV in humans.
Bionor Pharma is exploring the possibility to combine Vacc-4x and Vacc-C5 into
one vaccine (Vacc-HIV), which as a therapeutic and possibly preventive HIV
vaccine potentially can eradicate HIV-infection.
Vaccines for other viral diseases
The Company's innovative technology platform is also well suited to develop
vaccines for other viral diseases, including Influenza, HCV (Hepatitis C), CMV
(Cytomegalovirus) and HPV (Human papillomavirus). The universal influenza
vaccine (Vacc-Flu) is in preclinical phase of development.
More information about Bionor Pharma is available at www.bionorpharma.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act). Vacc-4x, Vacc-C5, Vacc-Flu, Vacc-HCV,
Vacc-CMV and Vacc-HPV are investigational treatments that have not been
approved for marketing by any regulatory authority.
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Bionor Pharma ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.